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Abstract We examined expression of N-methylpurine-DNA
glycosylase (MPG), a DNA repair enzyme that removes N-
alkylpurine damage, in normal, malignant, and immortalized
breast epithelial cells, and breast cancer cell lines (MDA-MB-
231, MCF7, T47D). Northern analysis showed increased
expression in cancer versus normal breast epithelial cells (2^24-
fold). Southern blots revealed no gene amplification or poly-
morphisms. Immunofluorescence, immunohistochemistry, and
Western blot analysis demonstrated increased MPG protein
expression in the tumor cells that correlated with elevated
glycosylase activity. Since MPG overexpression has been shown
to be paradoxically associated with increased susceptibility to
DNA damage, up-regulation of this gene may suggest a
functional role in breast carcinogenesis.
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1. Introduction
The human genome is continually exposed to exogenous
and endogenous alkylating and oxidative agents that result
in damage to DNA. If left unrepaired, DNA damage may
lead to carcinogenesis, cell death, and aging [1,2]. The nitro-
gen moieties of the purine rings are the main target for alky-
lation damage from environmental methylating agents [3].
These N-alkylpurines: 7-methylguanine, 3-methyladenine,
and 3-methylguanine, are among the most prevalent DNA
adducts produced by simple alkylating agents and are re-
moved by ubiquitous base excision repair processes involving
the action of various enzymes [3]. The ¢rst step of the N-
alkylpurine repair process is the glycolytic removal of the
modi¢ed base by N-methylpurine-DNA glycosylase [2]. Re-
moval of N-alkylpurines leads to the formation of apurinic
sites, that are subsequently removed by excision base repair
[2,3]. Although N-alkylpurines have not been found to be
directly mutagenic, apurinic sites left by this repair process
can block replication and lead to mutation [4]. In addition
to the repair of N-alkylpurines and other related adducts,
N-methylpurine-DNA glycosylase also participates in repair
of 8-hydroxyguanine [5] and hypoxanthine [6].
Human N-methylpurine-DNA glycosylase has been cloned
and characterized by several groups [7^10]. Although in-
creased expression of this enzyme can be transcriptionally
induced in rat hepatoma cells by DNA-damaging agents
[11], it appears that during the multi-step repair of N-alkyl-
purines, MPG activity may not be rate limiting, and cells may
contain this protein in excess. There are con£icting data re-
garding the biological role of N-methylpurine-DNA glycosy-
lase in determining resistance to alkylating agents. Increased
repair due to overexpression of MPG has not been shown to
give rise to increased resistance to methylating agents in var-
ious cell lines [12^15]. Instead, overexpression of this enzyme
was found to contribute to the formation of sister chromatid
exchanges, chromosomal aberrations, and gene mutations,
possibly due to incomplete excision repair [13]. While the ex-
pression of this enzyme has not been found to be a determi-
nant of resistance of cells to cytotoxic alkylating drugs in
either human breast cancer [15] or rat hepatoma [14] cell lines,
repair de¢cient MPG homozygous mutant mouse cells exhib-
ited increased sensitivity to alkylation-induced chromosome
damage and cell killing [16]. In sum, these studies suggest
that the balance between glycosylase activity, leading to apur-
inic sites and subsequent formation of strand breaks, and
subsequent excision repair processes may play an important
role in determining cellular cytotoxicity and resistance to al-
kylating agents.
In considering the proposed role of DNA base lesions in
mutagenesis and carcinogenesis, we investigated expression of
this enzyme in human breast cancer. Levels of N-methylpur-
ine-DNA glycosylase messenger RNA were found to be over-
expressed up to 24-fold in breast cancer as compared to nor-
mal primary breast epithelium. MPG protein expression and
glycosylase activity was evaluated in the breast cancer cell
lines and was found to be increased as well.
2. Materials and methods
2.1. Materials
Breast tissues were obtained from the National Cancer Institute
Cooperative Human Tissue Network (Columbus, OH) and included
normal breast from reduction mammoplasty patients and in¢ltrating
ductal carcinoma. Specimens were collected fresh from surgery and
either processed for tissue culture as described previously [17] or fro-
zen down in liquid nitrogen within 1 h of surgery. Tissue culture
reagents were obtained from GibcoBRL (Gaithersburg, MD) and
supplements were either from Sigma (St. Louis, MO) or Collaborative
Research Inc. (Bedford, MA). Blotting membranes and reagents used
for labeling of probes for Northern and Southern analysis were from
Amersham (Arlington Heights, IL). Immunoblotting reagents were
from Bio-Rad Labs (Hercules, CA). The human cloned cDNA en-
coding MPG [8], kindly provided by Dr. S. Mitra (University of
Texas Medical Branch), was used as a probe for Northern and South-
ern analysis. Two rabbit polyclonal antisera (HRP Inc., Denver,
PA), raised to peptides near the N-(SRGGRQTPRNTGM)- or C-
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(DQRDLAQDEAVWLERG)-terminal ends of the human cloned
MPG [8], were used for immunoassays. Puri¢ed human MPG was
kindly donated by Dr. T. O’Connor (City of Hope, Beckman Re-
search Institute, CA). 1,N6-Ethenoadenine and 1,N6-Etheno-2P-deox-
yadenosine standards were purchased from Sigma (St. Louis, MO).
Etheno-dA-CE phosphoramidite, used in the synthesis of the (OA)-
containing 25-base oligonucleotide utilized for DNA glycosylase ac-
tivity assays, was from Glen Research (Sterling, VA). The (OA)-con-
taining 25-base oligonucleotide sequence 5P-CCG-CT(OA)-GCG-
GGT-ACC-GAG-CTC-GAA-T-3P, and its complementary strand,
3P-GGC-GAT-CGC-CCA-TGG-CTC-CAG-CTT-A-5P, were taken
from Rydberg et al. [27]. Oligonucleotides were synthesized by the
Biotechnology Laboratories at Northwestern University. All other
reagents used in this study were from Sigma unless otherwise speci-
¢ed.
2.2. Cell culture
Normal human mammary epithelial cells used in this study were
primary cultures derived from individual surgical specimens. Brie£y,
cells were culled and grown in MCDB-170 medium plus serum-free
supplements as described previously [17]. Human breast cancer and
immortalized epithelial cells were established cell lines obtained from
the American Tissue Culture Collection (Rockville, MD). MCF10A,
an immortalized, non-transformed breast epithelial cell line derived
from a normal reduction mammoplasty specimen, was maintained
in a 1:1 mix of Ham’s F12 and DMEM supplemented with 5%
heat inactivated equine serum, 500 ng/ml hydrocortisone, 20 ng/ml
epidermal growth factor (EGF), 100 ng/ml cholera toxin, and
0.01 mg/ml insulin. Breast cancer cell lines were cultured in RPMI-
1640 medium plus 10% fetal bovine serum (FBS) supplemented with
either 0.01 mg/ml insulin, for T47D cells, or 0.292 mg/ml glutamine,
for MCF7 and MDA-MB-231 cells. Cells were routinely passaged at
near-con£uence with Trypsin-EDTA.
2.3. Northern blot analysis
Total RNA was prepared from breast cancer tissues and from ex-
ponentially growing cells using trizol reagent (GibcoBRL), according
to manufacturer’s directions. Samples of 30 Wg of total RNA were
electrophoresed in denaturing 1.2% agarose/formaldehyde gels and
transferred by capillary action to Hybond-N (Amersham) in
20USSC, following the manufacturer’s recommendations. Blots
were ¢xed and pre-hybridized at 42‡C for 3 h in hybridization bu¡er
(5USSPE, 5UDenhardt’s, 0.5% SDS, 50% formamide, 100 Wg/ml
Herring sperm DNA). Hybridization followed for 24 h at the same
temperature with a 32P-MPG cDNA probe, prepared by the random
primer Redivue method (Amersham). Membranes were successively
washed following hybridization in 2USSC/0.1% SDS (twice quickly
at room temperature and once for 20 min at 60‡C), 1USSC/0.1% SDS
(once 20 min at 60‡C), and 0.1USSC/0.1% SDS (once 20 min at
60‡C). Autoradiographs were exposed for periods of time to ensure
that signal saturation did not occur. Blots were stripped and reprobed
with 32P-human glyceraldehyde phosphate dehydrogenase (GAPDH),
as internal reference.
2.4. Southern blot analysis
Genomic DNA was prepared from cultured cells according to Ma-
niatis et al. [18]. DNA samples (15 Wg) were digested with EcoRI,
BamHI, or HindIII (GibcoBRL), electrophoresed in 0.7% agarose,
and capillary blotted on to Hybond-N+ (Amersham, IL) in 0.4 M
NaOH. The hybridization and washing protocols for blots were the
same as those described for Northern blotting with the exception of a
16 h hybridization period at 42‡C of 32P-MPG cDNA probe. Follow-
ing washes, blots were autoradiographed.
2.5. Immunoblotting assays
Total protein was obtained from whole cell lysates from exponen-
tially growing cells using RIPA bu¡er (50 mM Tris/HCl pH 8.0,
150 mM NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS) and
protease inhibitors. Brie£y, cells were seeded in 100U20 mm tissue
culture dishes (VWR, McGaw Park, IL) and cultured to 50% con£u-
ence, rinsed with phosphate bu¡ered saline (PBS), and lysed in 0.5 ml
of RIPA bu¡er for 45 min on ice. 60 Wg protein/lane were subjected to
SDS-PAGE on 12% polyacrylamide gels, transferred to nitrocellulose
membranes, and processed for immunoblotting as previously de-
scribed [19], using polyclonal rabbit antiserum directed against the
N-terminal end of human MPG. Red ponceau staining of blots was
routinely performed to verify equal loading of lanes. Blots were de-
veloped by chemiluminescence using the ECL detection Western blot-
ting system (Amersham) and autoradiographed.
2.6. Immuno£uorescence
Normal or malignant breast cells were seeded on culture slides at
(VWR) 4U103 cells/well and grown for 24^48 h to 30% con£uence.
Slides were washed three times in PBS, pH 7.4, ¢xed in 100% meth-
anol for 5 min, permeabilized in acetone for 2 min at 320‡C, and
allowed to air dry. Fixed cells were incubated with rabbit polyclonal
antiserum raised to the C-terminal end of the human MPG (diluted
1:2000 in PBS 10% FBS) for 1 h at 37‡C in a humidi¢ed atmosphere.
Following incubation, cells were rinsed 3U with PBS, incubated 30
min with 5% normal goat serum (Jackson ImmunoResearch, West
Grove, PA) to block non-speci¢c staining, washed 3U with PBS,
and incubated with goat anti-rabbit rhodamine conjugated secondary
antibody (Southern Biotech. Associates, Birmingham, AL) diluted in
PBS 1:40 for 45 min at 37‡C. Following staining, cells were rinsed 3U
with PBS, once with Tris-saline (pH 8.2) at 4‡C, and blot dried.
Coverslips were then mounted on slides with gelvatol (vinol 203;
Air Products and Chemicals, Allentown, PA), containing 25 mg/ml
of 1,4-Diazabicyclo[2.2.2]octane (Sigma) to reduce £uorescence
quenching, and allowed to dry. Control slides with non-immune se-
rum were also prepared. Fluorescence samples were visualized using a
Zeiss Photomicroscope III ¢tted with epi£uorescence optics (Zeiss
Inc., Thornwood, NY). Photographs were taken using the same ex-
posure, images were stored on Sony optical discs and printed on a
Tektronix printer (Tektronix, Wilsonville, OR).
2.7. Immunohistochemistry
For immunohistochemical analysis of MPG, a titration assay was
used to estimate the approximate amount of MPG [20]. Immunohis-
tochemical assays were performed on both thin prep cytology samples
¢xed for 10 min as well as formalin-¢xed para⁄n-embedded cell pel-
lets processed and cut at 4 microns. Brie£y, formalin-¢xed para⁄n-
embedded cell lines were depara⁄nized in xylene and appropriately
¢xed as previously described [20]. Non-speci¢c staining was blocked
by pretreating with normal goat serum (Vector Laboratories Inc,
Burlingame, CA) in PBS 1% bovine serum albumin (BSA) for
15 min in a humidity chamber at room temperature. Slides were in-
cubated overnight at 4‡C with primary antibody, raised to a peptide
near the C-terminal end of human MPG, in PBS 1% BSA or preim-
mune rabbit serum. Following rinses, 1U in 1% Tween 20 for 10 min
and 3U in PBS 5 min each, immunoreactivity was made visible by
incubating with biotinylated goat anti-rabbit secondary antibody
(Vector) in PBS 1% BSA for 30 min at room temperature. After
incubation, cells were rinsed 3U in PBS for 10 min each and incu-
bated with streptavidin-horseradish peroxidase (HRP) (Zymed Labo-
ratories, Inc., South San Francisco, CA) in PBS 1% BSA for 30 min.
After three rinses in PBS for 10 min, working diaminobenzidine
(DAB, Sigma) was added as substrate for 5 min at room temperature,
consisting of 0.6% DAB and 0.01% hydrogen peroxide in PBS 1%
BSA. Cells were then rinsed 3U in PBS for 10 min total, 2U in
distilled water, and counterstained with 1% methyl green for 30 s.
Slides were washed at least four times in distilled water until stain
no longer came o¡ and dehydrated by dipping ten times each through
two changes of 70%, 95%, and absolute ethanol. Slides were cleared in
four changes of xylene for 1 min each and coverslips were mounted
with permount or other xylene miscible mounting medium.
2.8. Construction of recombinant GST-MPG fusion proteins
Construction, expression, and puri¢cation of recombinant GST-
MPG fusion proteins was carried out according to the GST gene
fusion system (Pharmacia Biotech, New Jersey). Construction of the
pGEX-3XMPG fusion vector was performed using standard cloning
techniques and procedures [18]. E. coli strain BL21 containing pGEX-
3XMPG fusion vector was grown in 2X-YTA medium at 30‡C to
A600 = 0.9. Isopropyl-L-D-thiogalactopyranoside (IPTG) was added
to a ¢nal concentration of 0.4 mM and cultures were harvested 2 h
later. GST-MPG fusion proteins were prepared from bacterial soni-
cates and puri¢ed using glutathione sepharose 4B according to the
instructions for the Bulk GST Puri¢cation Module (Pharmacia). Fu-
sion proteins were eluted with 50 mM Tris-HCl (pH 8), 5 mM reduced
glutathione, 20% glycerol, 1 mM PMSF, and 2 Wg aprotinin. The
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supernatant was removed, aliquoted, and frozen in liquid nitrogen,
and stored at 370‡C. The supernatant contained GST activity, meas-
ured using the CDNB assay from Pharmacia (data not shown). GST-
MPG fusion proteins were analyzed by SDS-PAGE and detected by
Western blot with both the anti-GST antibody contained in the GST
Detection Module (Pharmacia) and rabbit polyclonal antisera raised
against human MPG (data not shown).
2.9. DNA glycosylase activity assay
The (OA)-containing 25-base oligonucleotide sequence and condi-
tions used for the determination of DNA glycosylase activity were
according to Rydberg et al. [27]. The duplex oligodeoxynucleotide
was annealed by combining equal moles of the 25-base (OA)-oligo
and its complementary strand in 150 mM Tris pH 8, 30 mM MgCl2,
heating for 2 min at 95‡C, and allowing the mixture to cool down
slowly to room temperature. Crude cell extracts were prepared from
exponentially growing cells. Brie£y, cells were washed three times with
cold PBS, scraped from dishes, and collected by centrifugation at 4‡C
(500Ug, 5 min). Cells were then resuspended in cold bu¡er containing
50 mM Tris-HCl (pH 8.5), 1 mM EDTA, 1 mM DTT, and 10%
glycerol, supplemented with protease inhibitors as indicated above,
and disrupted by sonication on ice. After centrifugation (14 000Ug,
20 min) at 4‡C to pellet debris, supernatants were aliquoted and
stored at 380‡C. Equal amounts of crude cell extracts (100 Wg of
protein), puri¢ed human MPG protein (1 Wg), or puri¢ed recombinant
MPG-GST (3 Wg), were incubated with 20 pmol of (OA)-containing
double-stranded oligonucleotide in 35 mM HEPES-KOH, 0.5 mM
EDTA, 0.5 mM DTT, and 40 mM KCl (pH 7.2), for 4 h at 37‡C.
Low molecular weight products were then separated from bulk pro-
tein and oligonucleotide by ultra¢ltration using Ultrafree-MC
NMWL 30,000 (Millipore, Bedford, MA). Analysis of OA released
from the 25-mer oligonucleotide was performed by reverse-phase
HPLC on a Prodigy 5 Wm ODS 2 column (Phenomenex Inc., Tor-
rance, CA), using a gradient of 0^20% methanol for 15 min, followed
by constant 20% methanol for an additional 15 min at a £ow rate of
0.9 ml/min. Fluorescence detection and quantitation of OA was ac-
complished using a Shimadzu RF-551 spectro£uorometric detector at
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Table 1
Immunohistochemical reactivity: intensity of nuclear staining
Cell line Pre 1:500 Pre 1:1000 1:500 1:1000 1:2000
T47D nega bg neg 3+b 2+ 1+
MCF7 neg bg neg 2+ 1+ þ
MDA-MB-231 neg bg neg þ neg neg
Immunohistochemical data: formalin-¢xed para⁄n-embedded cell lines. Expression of MPG protein using polyclonal rabbit antiserum and
preimmune bleed (‘Pre’).
aneg, no staining; bg, cytoplasmic or perimembranous background staining, faint.
b þ to 3+, intensity score; positive, nuclear brown stain.
These ¢ndings were supported by end-point titration assays as well, which demonstrated loss of staining by MCF7 prior to T47D with antibody
dilution.
Fig. 1. Expression of MPG mRNA in cultured normal and tumor
cell lines. Panel A: Northern blot analysis of MPG in human nor-
mal and tumor breast cells. 30 Wg of total RNA from cultured tu-
mor cell lines and from normal breast epithelial cells were electro-
phoresed in 1.2% agarose and transferred to nylon membrane. Blots
were hybridized with an MPG cDNA probe, washed, and reprobed
with human glyceraldehyde phosphate dehydrogenase (GAPDH) to
control for di¡erences in loading. Upper panel, MPG transcripts
from normal breast epithelial cells (lane 1) and cultured normal and
tumor cell lines, MCF10A, MCF7, MDA-MB-231, and T47D (lanes
2^5, respectively). Lower panel, ¢lter reprobed for GAPDH as inter-
nal reference. Panel B: Data were collected from densitometric
measurement of the amount of MPG and GAPDH mRNAs and
values expressed in arbitrary units as normalized levels of MPG ex-
pression calculated from the quotient of MPG/GAPDH within each
experiment. Error bars represent the standard deviation of the mean
of ¢ve di¡erent experiments. Signi¢cance of ¢ndings was evaluated
by Student’s t-test comparing groups to the normal primary epithe-
lial cell control group, P6 0.05 is indicated by an asterisk (*).
C
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an excitation wavelength of 290 nm and an emission wavelength of
410 nm, coupled with a Hitachi HSM model D-7000 data analysis
program.
3. Results
3.1. Expression of N-methylpurine-DNA glycosylase mRNA
in human breast cell lines
To investigate the role of N-methylpurine-DNA glycosylase
in breast cancer, we examined its expression in normal breast
epithelial cells from primary culture (n = 6), an immortalized
breast epithelial cell line (MCF10A), and three breast cancer
cell lines (MDA-MB-231, MCF7, and T47D). Analysis of
steady-state RNA indicated the presence of a single 1.1 kb
transcript (Fig. 1A). A 1.1 kb MPG transcript was also ob-
served by Chakravarti et al. [8] in a variety of rat and human
cell lines using the same MPG cDNA probe and by others in
di¡erent human transformed cell lines [10]. The abundance of
the mRNA in all cells was determined by densitometric meas-
urement of the amount of MPG transcript standardized to
GAPDH. N-methylpurine-DNA glycosylase mRNA in im-
mortalized (non-transformed) breast epithelial MCF10A cells
and breast cancer cell lines MDA-MB-231, MCF7, and T47D,
was increased by approximately 2-, 2-, 5-, and 7-fold, respec-
tively, above normal breast epithelial cells (Fig. 1B). Southern
analysis of genomic DNAs from these lines generated identi-
cal patterns, suggesting a lack of genetic polymorphism
among the lines, and indicated no MPG ampli¢cation (data
not shown).
3.2. MPG protein expression in human breast cell lines
Protein expression in human breast cells was investigated in
whole cell protein extracts by Western blot, using rabbit poly-
FEBS 20461 13-7-98
Fig. 3. Immuno£uorescent staining for MPG in human breast cells. Human normal (N148) and malignant (MCF7, T47D) breast cells, were
cultured on glass slides, ¢xed, and processed for indirect immuno£uorescence microscopy using rabbit polyclonal MPG antiserum (A, E, I) or
preimmune serum (C, G, K). Fluorescence samples were visualized using a Zeiss Photomicroscope III ¢tted with epi£uorescence optics (Zeiss
Inc., Thornwood, NY). Photographs were taken using the same exposure, images were stored on Sony optical discs and printed on a Tektronix
printer (Tektronix, Wilsonville, OR). B, D, F, H, J, L: Phase contrast images of the cells. Bar, 25 Wm.
Fig. 2. Western blot analysis of MPG protein in whole-cell extracts
of human normal and tumor breast cells. 60 Wg of total protein
were resolved by SDS-PAGE on a 12% polyacrylamide gel, trans-
ferred to nitrocellulose membranes, and immunoblotted with rabbit
polyclonal anti-human MPG antiserum. 300 ng of puri¢ed human
MPG, kindly provided by Dr. T. O’Connor (City of Hope, Beck-
man Research Institute, CA), served as a marker in lane 1. Sizes of
molecular weight standards (kDa) are indicated on the right side.
The arrow denotes the MPG protein band (32 kDa). Western blot
analysis of MPG detected a 32 kDa protein that was increased 3-
and 6-fold in T47D and MCF7 cells respectively, as compared to
normal breast epithelial cells.
S.R. Cerda et al./FEBS Letters 431 (1998) 12^18 15
clonal anti-human MPG antiserum (Fig. 2). MPG protein
resolved as a 32 kDa protein band, as previously shown using
puri¢ed full length protein [21]. MPG protein was found to be
increased approximately 3- and 6-fold in T47D and MCF7
cells, as compared with normal breast epithelial cells.
Although the di¡erences in protein expression between cells
were smaller than with mRNA, possibly due to post-transla-
tional modi¢cations in these lines, MPG protein expression
was found to be higher in breast cancer cells as compared
with normal breast epithelial cells.
Immuno£uorescent staining for human MPG was subse-
quently investigated to study localization of MPG in human
breast cells. While normal primary breast cells (N148) showed
nuclear staining of MPG, the breast tumor cells exhibited
both a perinuclear and nuclear staining pattern (Fig. 3). In-
tensity of nuclear staining was semi-quantitated by immuno-
histochemistry in the breast cancer cell lines and MPG nuclear
staining was found to correlate with mRNA expression (Table
1).
3.3. DNA glycosylase activity by quantitation of OA release
in human breast cell lines
Crude cell extracts from human breast cells were incubated
with 20 pmol of a synthetic oligonucleotide containing OA and
release of the free base was identi¢ed after reverse-phase
HPLC using £uorescence detection as previously described
[27]. Both standards 1,N6-Ethenoadenine (OA) and 1,N6-Ethe-
no-2P-deoxyadenosine showed distinct peaks that were clearly
separated by approximately 2 min and had retention times of
approximately 16.8 and 19.45 min respectively. DNA glyco-
sylase activity was expressed as pmoles of OA released per
hour in 100 Wg of protein from crude cell extracts made
from normal (MCF10A) and cancer (MDA-MB-231,
MCF7, and T47D) human breast cell lines (Table 2). Release
of (OA) was also measured using puri¢ed human N-methyl-
purine-DNA glycosylase (1 Wg) and recombinant GST-MPG
fusion protein (3 Wg) as controls. As shown in Table 2, DNA
glycosylase activity was increased approximately 4-5-fold in
T47D and MCF7 cells, as compared with MDA-MB-231
and MCF10A cells (Table 2).
3.4. Expression of N-methylpurine-DNA glycosylase mRNA
in human breast tumor tissues
In vivo expression of N-methylpurine-DNA glycosylase
mRNA was investigated in 13 human primary breast cancer
tissues and breast epithelium from six normal individuals.
Tissues included normal breast from reduction mammoplasty
patients and in¢ltrating ductal carcinoma. Expression of
MPG message in tumor tissues was found to be increased
2^4-fold in three of the samples tested and 5^24-fold above
normal primary breast epithelium in the remaining samples
tested, with no overlap between the normal and malignant
groups (Fig. 4). In sum, these data suggest increased MPG
expression in breast cancer tissues.
4. Discussion
The main target for alkylation damage from environmental
methylating mutagens is purines in the DNA [3]. Cells possess
speci¢c DNA excision repair mechanisms that involve the
action of various enzymes implicated in the recognition and
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Table 2
DNA glycosylase activity releasing 1,N6-Ethenoadenine from (OA)-containing 25-base oligonucleotide
Total protein (Wg) Release of OA (pmol/h)
Puri¢ed MPG protein 1 2.892





Data shown are averages of two to three independent experiments. Indicated amounts of protein extract were incubated for 4 h at 37‡C in 120 Wl of
assay bu¡er containing 20 pmol of 25-mer synthetic oligonucleotide containing a single OA at the sixth position from the 5P end [27]. Release of the
free base was identi¢ed after reverse-phase HPLC using £uorescence detection at an excitation wavelength of 290 nm and an emission wavelength
of 410 nm.
Fig. 4. Steady-state mRNA expression of MPG in primary tumors
of the breast. 30 Wg of total RNA collected from breast cancer tis-
sues and from normal breast epithelial cells were electrophoresed in
1.2% agarose, blotted to nylon membrane, and hybridized with an
MPG cDNA probe. Blots were then washed and reprobed with hu-
man glyceraldehyde phosphate dehydrogenase (GAPDH) to control
for di¡erences in loading. Data were collected from densitometric
measurement of the amount of MPG and GAPDH mRNAs and
values expressed in arbitrary units as normalized levels of MPG ex-
pression calculated from the quotient of MPG/GAPDH within each
experiment. Data points are plotted in a scatter graph. No overlap
between groups was observed. Expression of MPG message in tu-
mors is increased 2^24-fold as compared with normal primary
breast epithelial cells.
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removal of these N-methylation products [1,3]. In addition to
repairing DNA alkylation damage, base excision repair mech-
anisms are involved in the repair of one of the most prevalent
products of oxygen radical injury, the mutagenic DNA lesion
8-hydroxydeoxyguanosine [5,23]. When these defenses cannot
keep pace with the degree of damage, such as under condi-
tions of high oxidative or alkylating stress, or when repair is
ine⁄cient, the miscoding potential of these lesions can result
in the accumulation of genetic defects that may contribute to
carcinogenesis [22]. High concentrations of these hydroxyl
radical-induced DNA base lesions have been found by others
in human breast cancers [24]. In considering the proposed role
of DNA base lesions in mutagenesis and carcinogenesis, we
investigated expression of one of the enzymes responsible for
repair of these DNA lesions, N-alkylpurine glycosylase, in
breast cancer.
In this study we have shown that the steady-state level of
MPG mRNA is consistently higher in human breast cancer
samples: three (MCF7, MDA-MB-231, and T47D) cell lines
and 13 primary tumors, as compared to normal human breast
epithelium (Figs. 1 and 4). Northern blot analysis showed a
1.1-kb transcript in human normal and tumor breast cells, as
previously seen for other human carcinoma cell lines [10] and
rat hepatocytes [14]. MPG protein levels were also found to be
higher in human breast cancer cell lines than in normal breast
epithelial cells (Fig. 2). While expression of MPG gene has
been shown to be constitutively expressed in di¡erent tissues
tested [8,10,11,14,25], consistent with its function as house-
keeping gene, high levels of MPG have also been reported
in some tumors, such as HT-29 cells derived from a colon
adenocarcinoma, when compared to other human trans-
formed cell lines [10]. The authors suggested that the environ-
mental exposure to alkylating agents in colon epithelium may
be particularly high. In contrast, normal rat hepatocytes were
found to exhibit increased levels of expression of this gene, as
compared to rat malignant hepatoma cell lines [14]. Expres-
sion of MPG may be dictated by various types and levels of
carcinogen exposure in di¡erent tissues.
The possibility that overexpression of MPG in the human
breast tumor cell lines could be due to gene ampli¢cation was
ruled out in Southern blot analysis, which also revealed no
evidence of genetic polymorphisms. In contrast, the highly
aneuploid human HeLa MR cell line has shown polymor-
phisms in this gene [8]. It has been reported that MPG
mRNA can be weakly induced in some cells 24 and 48 h after
mutagen exposure [11,25], while other studies on the induci-
bility of the rat MPG promoter have not shown a signi¢cant
induction by DNA methylating agents and ionizing radiation
[26]. However, activity of the rat MPG promoter can be in-
duced by UV light and the tumor promoter 12-O-tetradeca-
noylphorbol 13-acetate [26]. While MPG de¢cient mouse cells
are more sensitive to chromosome damage and cell killing
induced by methylating agents [16], overexpression of this
enzyme has not been demonstrated to increase protection
against the cytotoxic and mutagenic e¡ect of alkylating agents
[12^15]. In fact, cells overexpressing MPG were found to ex-
hibit increased chromosomal damage and gene mutations,
possibly due to imbalance in the multi-step process of DNA
excision repair [13]. If overall repair would then depend upon
downstream repair pathways such as apurinic endonucleases,
MPG overexpression, leading to increased apurinic sites not
compensated by downstream repair pathways, might contrib-
ute to carcinogenesis. Our data suggest either that overexpres-
sion of this gene might contribute to breast cancer develop-
ment through imbalanced repair or might be utilized as a
protective mechanism by breast cancer cells in response to
elevated levels of DNA adducts found in breast cancerous
tissue [24]. Although all cell types exhibited nuclear MPG
staining (Fig. 3), a high intensity of this staining was localized
outside of the nucleus in the breast cancer cells, where DNA
damage cannot be induced. This di¡erence in nuclear local-
ization/transport of MPG in breast tumor cells as compared
to normal breast epithelial cells, possibly due to post-trans-
lation modi¢cations, could re£ect a de¢ciency in nuclear DNA
repair mechanisms in the breast cancer cells investigated in
this study. With this in mind, DNA glycosylase activity was
determined in the breast cancer cell lines and was found to be
increased 4-5-fold in T47D and MCF7 cells respectively, as
compared with MCF10A and MDA-MB-231 cells, correlating
with protein expression (Table 2 and Fig. 2). Although we
cannot tell at this point whether increased expression of this
enzyme is a helpful adaptation to increased adduct formation
or decreased transport, or, conversely, a detrimental response,
data suggest up-regulation of MPG in breast cancer. We are
currently addressing this issue in our laboratory. Additionally,
animal models using transgenic mice overexpressing this en-
zyme are being developed to determine the in vivo role of
MPG in breast carcinogenesis.
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